ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) has begun the closing procedures for its acquisition of Alimera Sciences, Inc. (Nasdaq: ALIM). The deal, previously announced, is expected to complete today, pending satisfaction or waiver of the remaining customary closing conditions. ANI Pharmaceuticals is a diversified biopharmaceutical company focused on developing and marketing branded and generic prescription pharmaceutical products. The company aims to drive growth through its Rare Disease business, generics, innovative established brands, and U.S.-based manufacturing capabilities. The forward-looking statements included with this announcement outline beliefs, expectations, and risks associated with the transaction, which are stipulated under the Private Securities Litigation Reform Act of 1995.
Biopharmaceutical Industry, Mergers and Acquisitions,United States
https://www.globenewswire.com/news-release/2024/09/16/2946466/0/en/ANI-Pharmaceuticals-Initiates-Closing-of-Acquisition-of-Alimera-Sciences.html